Skip to main content

Estradiol Transdermal System 75mcg/day (0.075mg/day) (Sandoz, USA)

Section 19A approved medicine
Estradiol Transdermal System 75mcg/day (0.075mg/day) (Sandoz, USA)
Section 19A approval holder
Sandoz Pty Ltd ABN 60 754 449 553
1800 726 369
Approved until
Medicines in short supply/unavailable
ESTRADOT 75 estradiol 75 microgram transdermal drug delivery system sachet - ARTG 338059

Short term treatment of symptoms of estrogen deficiency due to the menopause, whether natural or surgically induced. In women with an intact uterus, estrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals. Combination HRT should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.

Picture of Estradiol Transdermal System 75mcg/day (0.075mg/day)

Help us improve the Therapeutic Goods Administration site